Literature DB >> 26983689

Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer.

Priya S Mathur1, Jessica J Gierut1, Grace Guzman2, Hui Xie3, Rosa M Xicola4, Xavier Llor4, Michael I Chastkofsky1, Ansu O Perekatt1, Angela L Tyner5.   

Abstract

UNLABELLED: Disruption of the gene encoding Protein Tyrosine Kinase 6 (Ptk6) delayed differentiation and increased growth in the mouse intestine. However, Ptk6-null mice were also resistant to azoxymethane-induced colon tumorigenesis. To further explore functions of PTK6 in colon cancer, expression of epithelial and mesenchymal markers, as well as proliferation, migration, and xenograft tumor growth, was examined in human colon tumor cell lines with knockdown or overexpression of PTK6. PTK6 protein, transcript, and activation were also examined in a human colon tumor tissue array, using immunohistochemistry and qRT-PCR. Knockdown of PTK6 led to the epithelial-mesenchymal transition (EMT) in SW480 and HCT116 cells, whereas overexpression of PTK6 in SW620 cells restored an epithelial phenotype in a kinase-independent manner. PTK6 knockdown also increased xenograft tumor growth of SW480 cells, suggesting tumor suppressor functions. In clinical specimens, PTK6 expression was highest in normal differentiated epithelial cells and reduced in tumors. In contrast, overexpression of constitutively active PTK6 promoted STAT3 and ERK5 activation in colon cancer cells, and endogenous PTK6 promoted cell survival and oncogenic signaling in response to DNA-damaging treatments. These data indicate that PTK6 has complex, context-specific functions in colon cancer; PTK6 promotes the epithelial phenotype to antagonize the EMT in a kinase-independent manner, whereas activation of PTK6 promotes oncogenic signaling. IMPLICATIONS: Understanding context-specific functions of PTK6 is important, because although it promotes cell survival and oncogenic signaling after DNA damage, expression of PTK6 in established tumors may maintain the epithelial phenotype, preventing tumor progression. Mol Cancer Res; 14(6); 563-73. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26983689      PMCID: PMC4912439          DOI: 10.1158/1541-7786.MCR-15-0450

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  50 in total

1.  Selection and validation of differentially expressed genes in head and neck cancer.

Authors:  M A Kuriakose; W T Chen; Z M He; A G Sikora; P Zhang; Z Y Zhang; W L Qiu; D F Hsu; C McMunn-Coffran; S M Brown; E M Elango; M D Delacure; F A Chen
Journal:  Cell Mol Life Sci       Date:  2004-06       Impact factor: 9.261

2.  Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma.

Authors:  Stephanie Ma; Jessie Y J Bao; Pak Shing Kwan; Yuen Piu Chan; Carol M Tong; Li Fu; Na Zhang; Amy H Y Tong; Yan-Ru Qin; Sai Wah Tsao; Kwok Wah Chan; Si Lok; Xin-Yuan Guan
Journal:  Gastroenterology       Date:  2012-06-13       Impact factor: 22.682

3.  Disruption of the mouse protein tyrosine kinase 6 gene prevents STAT3 activation and confers resistance to azoxymethane.

Authors:  Jessica Gierut; Yu Zheng; Wenjun Bie; Robert E Carroll; Susan Ball-Kell; Andrea Haegebarth; Angela L Tyner
Journal:  Gastroenterology       Date:  2011-07-08       Impact factor: 22.682

4.  Differential expression of the non-receptor tyrosine kinase BRK in oral squamous cell carcinoma and normal oral epithelium.

Authors:  B J Petro; R C Tan; A L Tyner; M W Lingen; K Watanabe
Journal:  Oral Oncol       Date:  2004-11       Impact factor: 5.337

5.  A susceptibility gene set for early onset colorectal cancer that integrates diverse signaling pathways: implication for tumorigenesis.

Authors:  Yi Hong; Kok Sun Ho; Kong Weng Eu; Peh Yean Cheah
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

6.  BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.

Authors:  Elisa Sala; Luca Mologni; Silvia Truffa; Carlo Gaetano; Gideon E Bollag; Carlo Gambacorti-Passerini
Journal:  Mol Cancer Res       Date:  2008-05-05       Impact factor: 5.852

7.  Association between gene expression profile and tumor invasion in oral squamous cell carcinoma.

Authors:  Gokce A Toruner; Celal Ulger; Mualla Alkan; Anthony T Galante; Joseph Rinaggio; Randall Wilk; Bin Tian; Patricia Soteropoulos; Meera R Hameed; Marvin N Schwalb; James J Dermody
Journal:  Cancer Genet Cytogenet       Date:  2004-10-01

Review 8.  Context-specific protein tyrosine kinase 6 (PTK6) signalling in prostate cancer.

Authors:  Yu Zheng; Angela L Tyner
Journal:  Eur J Clin Invest       Date:  2013-02-10       Impact factor: 4.686

9.  Induction of protein tyrosine kinase 6 in mouse intestinal crypt epithelial cells promotes DNA damage-induced apoptosis.

Authors:  Andrea Haegebarth; Ansu O Perekatt; Wenjun Bie; Jessica J Gierut; Angela L Tyner
Journal:  Gastroenterology       Date:  2009-06-06       Impact factor: 22.682

10.  PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors.

Authors:  Maoyu Peng; Rajyasree Emmadi; Zebin Wang; Elizabeth L Wiley; Peter H Gann; Seema A Khan; Nilanjana Banerji; William McDonald; Szilard Asztalos; Thao N D Pham; Debra A Tonetti; Angela L Tyner
Journal:  Oncotarget       Date:  2014-08-15
View more
  11 in total

Review 1.  Targeting protein tyrosine kinase 6 in cancer.

Authors:  Milica B Gilic; Angela L Tyner
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-09-18       Impact factor: 10.680

2.  Breast Tumor Kinase (Brk/PTK6) Mediates Advanced Cancer Phenotypes via SH2-Domain Dependent Activation of RhoA and Aryl Hydrocarbon Receptor (AhR) Signaling.

Authors:  Amy R Dwyer; Carlos Perez Kerkvliet; Raisa I Krutilina; Hilaire C Playa; Tiffany N Seagroves; Carol A Lange; Deanna N Parke; Warner A Thomas; Branden A Smeester; Branden S Moriarity
Journal:  Mol Cancer Res       Date:  2020-11-10       Impact factor: 6.333

3.  PTEN is a protein phosphatase that targets active PTK6 and inhibits PTK6 oncogenic signaling in prostate cancer.

Authors:  Darren J Wozniak; Andre Kajdacsy-Balla; Virgilia Macias; Susan Ball-Kell; Morgan L Zenner; Wenjun Bie; Angela L Tyner
Journal:  Nat Commun       Date:  2017-11-15       Impact factor: 14.919

4.  Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers.

Authors:  Luping Qiu; Kymberly Levine; Ketan S Gajiwala; Ciarán N Cronin; Asako Nagata; Eric Johnson; Michelle Kraus; John Tatlock; Robert Kania; Timothy Foley; Shaoxian Sun
Journal:  PLoS One       Date:  2018-06-07       Impact factor: 3.240

5.  SRF Potentiates Colon Cancer Metastasis and Progression in a microRNA-214/PTK6-Dependent Manner.

Authors:  Tao Li; Yingchun Wan; Ziyuan Su; Jiayu Li; Minna Han; Changyu Zhou
Journal:  Cancer Manag Res       Date:  2020-07-28       Impact factor: 3.602

6.  Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRASG13D.

Authors:  Susan A Kennedy; Mohamed-Ali Jarboui; Sriganesh Srihari; Cinzia Raso; Kenneth Bryan; Layal Dernayka; Theodosia Charitou; Manuel Bernal-Llinares; Carlos Herrera-Montavez; Aleksandar Krstic; David Matallanas; Max Kotlyar; Igor Jurisica; Jasna Curak; Victoria Wong; Igor Stagljar; Thierry LeBihan; Lisa Imrie; Priyanka Pillai; Miriam A Lynn; Erik Fasterius; Cristina Al-Khalili Szigyarto; James Breen; Christina Kiel; Luis Serrano; Nora Rauch; Oleksii Rukhlenko; Boris N Kholodenko; Luis F Iglesias-Martinez; Colm J Ryan; Ruth Pilkington; Patrizia Cammareri; Owen Sansom; Steven Shave; Manfred Auer; Nicola Horn; Franziska Klose; Marius Ueffing; Karsten Boldt; David J Lynn; Walter Kolch
Journal:  Nat Commun       Date:  2020-01-24       Impact factor: 14.919

Review 7.  Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 Signaling.

Authors:  Akshita B Bhatt; Saloni Patel; Margarite D Matossian; Deniz A Ucar; Lucio Miele; Matthew E Burow; Patrick T Flaherty; Jane E Cavanaugh
Journal:  Biomolecules       Date:  2021-01-29

8.  Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer.

Authors:  Chaoqun Liu; Zhihua Pan; Qian Chen; Zetao Chen; Weiwei Liu; Ling Wu; Muhong Jiang; Wandie Lin; Yujie Zhang; Weihao Lin; Rui Zhou; Liang Zhao
Journal:  J Exp Clin Cancer Res       Date:  2021-09-22

9.  Dephosphorylated parafibromin is a transcriptional coactivator of the Wnt/Hedgehog/Notch pathways.

Authors:  Ippei Kikuchi; Atsushi Takahashi-Kanemitsu; Natsuki Sakiyama; Chao Tang; Pei-Jung Tang; Saori Noda; Kazuki Nakao; Hidetoshi Kassai; Toshiro Sato; Atsu Aiba; Masanori Hatakeyama
Journal:  Nat Commun       Date:  2016-09-21       Impact factor: 14.919

10.  Overexpression of PTK6 predicts poor prognosis in bladder cancer patients.

Authors:  Xue-Lian Xu; Yun-Lin Ye; Zhi-Ming Wu; Qiu-Ming He; Lei Tan; Kang-Hua Xiao; Rui-Yan Wu; Yan Yu; Jia Mai; Zhi-Ling Li; Xiao-Dan Peng; Yun Huang; Xuan Li; Hai-Liang Zhang; Xiao-Feng Zhu; Zi-Ke Qin
Journal:  J Cancer       Date:  2017-09-27       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.